US2006269593A1PendingUtilityA1

Adjuvant for transcutaneous immunization

56
Assignee: US GOVERNMENTPriority: Nov 14, 1996Filed: Jan 19, 2006Published: Nov 30, 2006
Est. expiryNov 14, 2016(expired)· nominal 20-yr term from priority
A61P 37/04A61P 37/00A61K 9/08A61K 2039/54A61K 2039/55555A61K 9/107A61K 9/06A61K 2039/55544A61K 2039/55511B82Y 5/00A61K 9/127A61K 39/39A61K 2039/55566A61K 2039/55527A61K 9/7023A61K 2039/53A61K 39/00
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A transcutaneous immunization system delivers antigen to immune cells without perforation of the skin, and induces an immune response in an animal or human. The system uses an adjuvant, preferably an ADP-ribosylating exotoxin, to induce an antigen-specific immune response (e.g., humoral and/or cellular effectors) after transcutaneous application of a formulation containing antigen and adjuvant to intact skin of the animal or human. The efficiency of immunization may be enhanced by adding hydrating agents (e.g., liposomes), penetration enhancers, or occlusive dressings to the transcutaneous delivery system. This system may allow activation of Langerhans cells in the skin, migration of the Langerhans cells to lymph nodes, and antigen presentation.

Claims

exact text as granted — not AI-modified
1 - 49 . (canceled)  
     
     
         50 : A method of inducing an immune response to at least one antigen comprising applying a formulation to hydrated skin of an organism, wherein the formulation comprises an antigen which is derived from a pathogen, and wherein an effective amount of the antigen induces the immune response to the at least one antigen in the organism.  
     
     
         51 : The method of  claim 50 , wherein the pathogen is selected from the group consisting of bacterium, virus, fungus and parasite.  
     
     
         52 : The method of  claim 50 , wherein the antigen is selected from the group consisting of carbohydrate, glycolipid, glycoprotein, lipid, protein, lipoprotein, phospholipid, and polypeptide.  
     
     
         53 : The method of  claim 50 , wherein the pathogen is a live or an attenuated live virus and the antigen is expressed by the live or attenuated live virus.  
     
     
         54 : The method of  claim 51 , wherein the bacterium is anthrax.  
     
     
         55 : The method of  claim 51 , wherein the virus is rabies.  
     
     
         56 : The method of  claim 50 , wherein the formulation is a cream or gel or emulsion or ointment or lotion or paste or solution or suspension.  
     
     
         57 : The method of  claim 50 , wherein the formulation is applied with a patch.  
     
     
         58 : The method of  claim 50 , wherein the formulation further comprises a dressing.  
     
     
         59 : The method of  claim 58 , wherein the dressing is occlusive or non-occlusive.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.